UCSF Brain Tumor Center Clinical Trials
Our clinical trials evaluate a broad range of innovative therapies for both adults and children with brain tumors.
-
Recruiting
- Pediatrics
- On Hold
Conditions
Glioma
Glioblastoma (grade IV)
The FRONTIER Study is a prospective, interventional, single-arm, multi-center study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.
Conditions
Glioma
Glioblastoma (grade IV)
This is a phase 0/I exploratory study to evaluate the safety and toxicity profile of anti-TIGIT AB154 in combination with anti-PD-1 AB122 in patients with recurrent glioblastoma.
Conditions
Glioma
Glioblastoma (grade IV)
This phase I/II study is intended to explore a new potentially active mechanism of action that is cancer-specific in GBM patients who have exhausted standard of care that impacts survival.
Conditions
Glioma
This pilot study will assess the feasibility of using an implantable microdevice to measure local intratumor response to chemotherapy, immunotherapy, and other clinically relevant drugs in gliomas.
Conditions
Glioblastoma (grade IV)
Glioma
This is randomized multi-site phase II clinical trial that aims to assess whether a ketogenic diet improves overall survival in newly diagnosed glioblastoma patients who receive standard of care treatment when compared to the standard anti-cancer diet.
Conditions
Glioma
Glioblastoma (grade IV)
This is a randomized, double-blind, placebo-controlled study designed to examine the impact of a custom-formulated, high CBD product on measures of anxiety, quality of life, and tumor progression and imaging stability in newly-diagnosed glioblastoma patients.
Conditions
Glioma
Astrocytoma
Anaplastic astrocytoma (grade III)
Glioblastoma (grade IV)
Pleomorphic xanthoastrocytoma (grades II-III)
The phase I trial will evaluate the safety and efficacy of nivolumab and ipilimumab before and after surgery in treating children and young adults with recurrent or progressive high grade glioma.
Conditions
Glioma
Astrocytoma
Oligodendroglioma
This phase I/IIa study in patients with recurrent IDH-mutant glioma will investigate the safety and preliminary efficacy of AZD9574 in combination with temozolomide.
Conditions
Glioma
Astrocytoma
Diffuse astrocytoma (grade II)
Pilocytic astrocytoma (grade I)
Pleomorphic xanthoastrocytoma (grades II-III)
This phase III clinical trial will compare the efficacy of selumetinib compared to standard treatment with carboplatin/vincristine (CV) in patients with NF1-associated low-grade glioma (LGG).
Conditions
Glioma
Astrocytoma
Pilocytic astrocytoma (grade I)
Diffuse astrocytoma (grade II)
Pleomorphic xanthoastrocytoma (grades II-III)
This phase III clinical trial will evaluate the efficacy of selumetinib compared to treatment with carboplatin/vincristine (CV) in patients with low-grade glioma (LGG).
Conditions
Glioma
Glioblastoma (grade IV)
Astrocytoma
Oligodendroglioma
This is an international, open-label phase II clinical trial for recurrent patients who have a glioma harboring a BRAF abnormality.
Conditions
Glioma
Glioblastoma (grade IV)
This is a first-in-human phase I study to assess the safety and feasibility of using an IV infusion of E-SYNC T cells to treat patients with EGFRvIII-mutated glioblastoma (GBM).